Table 2 The features involved in prognostic models of OS, RFS and LR-RFS
| Â | Features | Level | p-value | Hazard Ratio | validation | |||
|---|---|---|---|---|---|---|---|---|
Point | 95% CI | Logistic regression | 5-fold cross validation | |||||
Lower | Upper | AUC (95% CI) | AUC (95% CI) | |||||
OS | ECOG (ref = 0 or 1) | 2 or 3 | 0.02 | 3.13 | 1.17 | 8.41 | 0.88 (0.78–0.97) | 0.81 (0.80–0.82) |
Vascular involvement (ref = 0) | 1 | 0.01 | 3.21 | 1.29 | 8.03 | |||
Lymphadenopathy (ref = 0) | 1 | 0.00 | 3.59 | 1.58 | 8.16 | |||
PC1a | Â | 0.04 | 1.24 | 1.02 | 1.51 | |||
RFS | Vascular involvement (ref = 0) | 1 | 0.01 | 3.06 | 1.40 | 6.70 | 0.86 (0.76–0.96) | 0.80 (0.792–0.81) |
Vascular attachment (ref = 0) | 1 | 0.00 | 3.46 | 1.65 | 7.25 | |||
Pleural retraction (ref = 0) | 1 | 0.01 | 3.24 | 1.41 | 7.42 | |||
Lymphadenopathy (ref = 0) | 1 | <.00 | 6.41 | 2.58 | 15.90 | |||
Relative enhancementa | Â | 0.05 | 1.40 | 1.00 | 1.96 | |||
LR-RFS | F13 (9b_3D_Circularity)a |  | 0.02 | 1.60 | 1.10 | 2.32 | 0.85 (0.74–0.95) | 0.80 (0.78–0.81) |
F92 (3D Laws features L5Â L5Â S5 Layer 1)a | Â | 0.00 | 1.96 | 1.35 | 2.83 | |||
Vascular involvement (ref = 0) | 1 | <.00 | 4.96 | 2.23 | 11.03 | |||
Lymphadenopathy (ref = 0) | 1 | 0.02 | 2.64 | 1.19 | 5.82 | |||